Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialJulio Rosenstock, Daisuke Yabe, David A. Cox et al.|The Lancet|2026Cited by 7